Navigation Links
Patients with treatment-resistant CLL respond positively to stem cell transplants
Date:7/2/2010

(WASHINGTON, July 1, 2010) Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology. About 15,000 new CLL cases were diagnosed in the United States in 2009 and about 4,000 deaths were documented (according to the American Cancer Society). While survival rates for leukemia have generally improved in the last decade, patients with rare, more aggressive forms of CLL do not respond well to standard chemotherapy-based and targeted treatments and often die within a few years of diagnosis.

Patients with CLL who are treatment-resistant (do not respond to chemotherapy and targeted antibody combination regimens) have been shown to have genetic abnormalities that predict their lack of response. In this study, researchers investigated whether alloSCT could be an effective treatment for this patient population, independent of underlying genetic abnormalities.

"This study, which is one of the largest of its kind, confirms that allogeneic stem cell transplants are a promising therapeutic option for treatment-resistant CLL patients fighting particularly aggressive disease, regardless of their genetic risk profile," said Peter Dreger, MD, of the Department of Medicine, University of Heidelberg, Germany, and lead author of the study. "However, because stem cell transplants come with serious risks, they should be reserved for only this group of patients until further studies can be done."

In alloSCT, blood stem cells are collected from a donor and then infused into the patient where they travel to the bone marrow and begin to produce new blood cells, replacing those that have been affected as a result of the disease. This type of treatment can pose serious complications, some of which are potentially fatal. In this prospective phase II study, a total of 90 patients with treatment-resistant CLL received alloSCT, and stem cell donors were either healthy siblings or unrelated, but matched, volunteers.

Prior to the transplant, patients in this study received conditioning, a standard therapy administered immediately before a stem cell transplant to help prepare the body to receive and accept the transplanted cells. The research team used a reduced-intensity conditioning approach with two common chemotherapies (fludarabine and cyclophosphamide) to reduce complications and allow the donor stem cells to fight the disease themselves.

After treatment with alloSCT, more than 40 percent of participants with this otherwise fatal disease enjoyed long-term freedom from relapse. These findings suggest that alloSCT is a feasible and potentially curative treatment for patients with high-risk CLL and should be considered for this patient population.


'/>"/>

Contact: Wendy Stokes
wstokes@hematology.org
202-552-4927
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Study shows short-term kidney failure in heart patients may not be as detrimental
2. Predicting Alzheimers Risk in Patients With Cognitive Problems
3. Beating doctor burnout and protecting patients
4. Fewer than half of breast cancer patients adhere to hormonal therapy regimen, study finds
5. Tray bleaching may improve oral health of elderly, special-needs patients
6. Brain Stimulation Seems to Boost Language Skills in Alzheimers Patients
7. Novel radiotracer shines new light on the brains of Alzheimers disease patients
8. Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression
9. Cardiac MRI in the ER cuts costs, hospital admissions for chest pain patients
10. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
11. What affects the gastrointestinal symptoms in peritoneal dialysis patients?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... , ... June 27, 2017 , ... Today, June 27th ... from PTSD. Yet less than 20% will receive adequate care due to lack of ... won't receive any care at all. And left untreated, veterans are at an increased ...
(Date:6/26/2017)... ... 2017 , ... Antoine Dental Center is now offering various types of dental implants ... as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant is ... sturdy, lasting new root for the tooth. , Several types of dental implants are ...
(Date:6/26/2017)... , ... June 26, 2017 , ... LARKR™ , ... health professionals in every state across the country to join its online treatment platform. ... way for therapists to reach a substantially greater number of people in need nationwide, ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro X ... the timeline and write in the lyrics to any song. ProLyric flies in the text ... of the text can be added modularly for optimal control. ProLyric makes editing any music ...
(Date:6/25/2017)... ... ... Health Month and the focus is on prostate cancer. Second only to skin cancer, ... most common cause of cancer related death today; lung cancer remains in the number one ... cancer during his lifetime. Those at highest risk are men who have a ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
(Date:5/30/2017)... CHICAGO , May 30, 2017 Hill-Rom Holdings, ... th Annual Global Healthcare Conference on Tuesday, June 13, ... John Greisch , Hill-Rom,s president and chief executive officer, ... The live audio webcast can be accessed at ... after conclusion of the live event through September 13, 2017. ...
Breaking Medicine Technology: